SGLT-2抑制-话题@MedSci

#SGLT-2抑制#

28篇内容 | 1447人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1793906, encodeId=c96c1e9390644, content=<a href='/topic/show?id=722516221ec' target=_blank style='color:#2F92EE;'>#SGLT-2抑制#</a>, objectTitle=Diabetes Obes Metab：SGLT-2抑制剂与下肢截肢风险！, objectType=article, longId=129835, objectId=b96412983500, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b96412983500, replyNumber=0, likeNumber=70, createdTime=2018-06-01, rootId=0, userName=yyj062, userId=052a130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b96412983500, moduleTitle=Diabetes Obes Metab：SGLT-2抑制剂与下肢截肢风险！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b96412983500)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793905, encodeId=092f1e93905bd, content=<a href='/topic/show?id=722516221ec' target=_blank style='color:#2F92EE;'>#SGLT-2抑制#</a>, objectTitle=Circulation：2型糖尿病患者初始SGLT-2抑制剂治疗获益良多, objectType=article, longId=111182, objectId=d149111182b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d149111182b8, replyNumber=0, likeNumber=70, createdTime=2017-09-16, rootId=0, userName=yyj062, userId=052a130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d149111182b8, moduleTitle=Circulation：2型糖尿病患者初始SGLT-2抑制剂治疗获益良多, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d149111182b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793904, encodeId=d1a41e939040b, content=<a href='/topic/show?id=722516221ec' target=_blank style='color:#2F92EE;'>#SGLT-2抑制#</a>, objectTitle=Circulation：SGLT-2抑制剂与其他降糖药对患者心脏衰竭和死亡风险的影响, objectType=article, longId=99260, objectId=9f869926077, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9f869926077, replyNumber=0, likeNumber=110, createdTime=2017-12-28, rootId=0, userName=yyj062, userId=052a130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9f869926077, moduleTitle=Circulation：SGLT-2抑制剂与其他降糖药对患者心脏衰竭和死亡风险的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9f869926077)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793903, encodeId=bbdb1e9390347, content=<a href='/topic/show?id=722516221ec' target=_blank style='color:#2F92EE;'>#SGLT-2抑制#</a>, objectTitle=CDS 2015：洪天配解读DPP-4抑制剂与SGLT-2抑制剂在糖尿病治疗中的协同作用, objectType=article, longId=60556, objectId=f8216055671, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f8216055671, replyNumber=0, likeNumber=75, createdTime=2016-10-17, rootId=0, userName=yyj062, userId=052a130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f8216055671, moduleTitle=CDS 2015：洪天配解读DPP-4抑制剂与SGLT-2抑制剂在糖尿病治疗中的协同作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f8216055671)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793902, encodeId=10671e939025d, content=<a href='/topic/show?id=722516221ec' target=_blank style='color:#2F92EE;'>#SGLT-2抑制#</a>, objectTitle=CDS 2015：纪立农教授公布SGLT-2抑制剂心血管终点（Empa-REG OT 研究）, objectType=article, longId=60553, objectId=902360553c9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=902360553c9, replyNumber=0, likeNumber=85, createdTime=2016-09-16, rootId=0, userName=yyj062, userId=052a130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=902360553c9, moduleTitle=CDS 2015：纪立农教授公布SGLT-2抑制剂心血管终点（Empa-REG OT 研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=902360553c9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793901, encodeId=bad01e93901f0, content=<a href='/topic/show?id=722516221ec' target=_blank style='color:#2F92EE;'>#SGLT-2抑制#</a>, objectTitle=郭艺芳：SGLT-2抑制剂——具有降糖作用的降压药, objectType=article, longId=60091, objectId=38b0600912e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=38b0600912e, replyNumber=0, likeNumber=70, createdTime=2016-04-06, rootId=0, userName=yyj062, userId=052a130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=38b0600912e, moduleTitle=郭艺芳：SGLT-2抑制剂——具有降糖作用的降压药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=38b0600912e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793899, encodeId=21301e93899ca, content=<a href='/topic/show?id=722516221ec' target=_blank style='color:#2F92EE;'>#SGLT-2抑制#</a>, objectTitle=Diabetes Care：SGLT-2抑制剂Empagliflozin添加胰岛素控制不佳的肥胖T2DM患者取得较好疗效（EMPA-REG MDI研究）, objectType=article, longId=36771, objectId=40bf36e716f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=40bf36e716f, replyNumber=0, likeNumber=76, createdTime=2015-03-17, rootId=0, userName=yyj062, userId=052a130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=40bf36e716f, moduleTitle=Diabetes Care：SGLT-2抑制剂Empagliflozin添加胰岛素控制不佳的肥胖T2DM患者取得较好疗效（EMPA-REG MDI研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=40bf36e716f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793900, encodeId=24811e93900c2, content=<a href='/topic/show?id=722516221ec' target=_blank style='color:#2F92EE;'>#SGLT-2抑制#</a>, objectTitle=礼来SGLT-2抑制剂闪亮登场——勃林格-礼来联盟美国推出降糖新药Jardiance, objectType=article, longId=39710, objectId=b27f39e10a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b27f39e10a3, replyNumber=0, likeNumber=62, createdTime=2014-12-22, rootId=0, userName=yyj062, userId=052a130, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b27f39e10a3, moduleTitle=礼来SGLT-2抑制剂闪亮登场——勃林格-礼来联盟美国推出降糖新药Jardiance, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b27f39e10a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

SGLT-2抑制

2020-05-29

yyj062 (审核中...)

前往app查看评论内容

#SGLT-2抑制#

Diabetes Obes Metab：SGLT-2抑制剂与下肢截肢风险！

2018-06-01

yyj062 (审核中...)

前往app查看评论内容

#SGLT-2抑制#

Circulation：2型糖尿病患者初始SGLT-2抑制剂治疗获益良多

2017-09-16

yyj062 (审核中...)

前往app查看评论内容

#SGLT-2抑制#

Circulation：SGLT-2抑制剂与其他降糖药对患者心脏衰竭和死亡风险的影响

2017-12-28

yyj062 (审核中...)

前往app查看评论内容

#SGLT-2抑制#

CDS 2015：洪天配解读DPP-4抑制剂与SGLT-2抑制剂在糖尿病治疗中的协同作用

2016-10-17

yyj062 (审核中...)

前往app查看评论内容

#SGLT-2抑制#

CDS 2015：纪立农教授公布SGLT-2抑制剂心血管终点（Empa-REG OT 研究）

2016-09-16

yyj062 (审核中...)

前往app查看评论内容

#SGLT-2抑制#

郭艺芳：SGLT-2抑制剂——具有降糖作用的降压药

2016-04-06

yyj062 (审核中...)

前往app查看评论内容

#SGLT-2抑制#

Diabetes Care：SGLT-2抑制剂Empagliflozin添加胰岛素控制不佳的肥胖T2DM患者取得较好疗效（EMPA-REG MDI研究）

2015-03-17

yyj062 (审核中...)

前往app查看评论内容

#SGLT-2抑制#

礼来SGLT-2抑制剂闪亮登场——勃林格-礼来联盟美国推出降糖新药Jardiance

2014-12-22

科室
- - 订阅+
  - 更多科室
工具
服务